Consistent efficacy of B/F/TAF in treatment-naïve HIV patients across different baseline HIV-1 RNA levels at week 48

To the Editor:Previous studies have demonstrated the efficacy of bictegravir(B),emtricitabine(F),and tenofovir alafenamide(TAF)in achieving virological suppression in human immunodeficiency virus(HIV)-infected patients.Virological suppression can be influenced by various factors,with baseline HIV-1 RNA being a critical consideration.Guidelines often use a baseline HIV RNA level of>500,000 copies/mL as the primary reference indicator for drug selection.[1]However,previous studies on the effectiveness of B/F/TAF have not specifically analyzed patients with baseline HIV RNA>500,000 copies/mL.In Chongqing,China,where the prevalence of advanced HIV among hospitalized patients living with HIV exceeds 70%,[2]up to 25%of patients have baseline HIV-1 RNA>500,000 copies/mL in our study,and many patients have opportunistic infections.In such a complex medical setting,the virological suppression rates of patients using B/F/TAF remain uncertain.